J. Brenneman

发表

(+)-Sorangicin A: evolution of a viable synthetic strategy.

R. J. Fox, Amos B. Smith, T. Maegawa, 2011, Tetrahedron.

Total synthesis of (+)-sorangicin A.

R. J. Fox, Amos B. Smith, Shuzhi Dong, 2009, Journal of the American Chemical Society.

Application of a domino intramolecular enyne metathesis/cross metathesis reaction to the total synthesis of (+)-8-epi-xanthatin.

S. Martin, David A. Kummer, J. Brenneman, 2005, Organic letters.

Synthesis and biological evaluation of novel, selective, nonsteroidal glucocorticoid receptor antagonists.

I. Akritopoulou‐Zanze, Jyoti R. Patel, P. Kym, 2004, Bioorganic & medicinal chemistry letters.

Application of intramolecular enyne metathesis to the synthesis of aza[4.2.1]bicyclics: enantiospecific total synthesis of (+)-anatoxin-a.

S. Martin, J. Brenneman, 2004, Organic letters.

Design, Synthesis, and Pharmacological Evaluation of Second Generation EZH2 Inhibitors with Long Residence Time.

P. Trojer, R. Sims, Shilpi Arora, 2020, ACS medicinal chemistry letters.

The Handbook of Continuous Crystallization

D. Shekhawat, Nima Yazdanpanah, J. Brenneman, 2020 .

Emerging therapeutics for the treatment of diabetic nephropathy.

S. Pullen, Jon Hill, J. Brenneman, 2016, Bioorganic & medicinal chemistry letters.

Ring‐Closing Metathesis as a Construct for the Synthesis of Polycyclic Alkaloids

S. Martin, J. Brenneman, 2006 .

Identification and characterization of second-generation EZH2 inhibitors with extended residence times and improved biological activity

P. Trojer, R. Sims, Shilpi Arora, 2021, The Journal of biological chemistry.

A soluble guanylate cyclase activator protects from diabetic nephropathy beyond standard of care in the ZSF1 rat

R. Fryer, Kathleen A. Lincoln, S. Pullen, 2015, BMC Pharmacology and Toxicology.

The Novel, Clinical-Stage Soluble Guanylate Cyclase Activator BI 685509 Protects from Disease Progression in Models of Renal Injury and Disease

R. Fryer, M. McHugh, Kathleen A. Lincoln, 2022, The Journal of Pharmacology and Experimental Therapeutics.

Abstract 3346: BBT-207, a novel, 4th generation, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with broad-spectrum activity to both treatment-emergent and drug-naïve mutants for the treatment of NSCLC

Sang-Yoon Lee, Mihee Song, J. Brenneman, 2022, Cancer Research.